CS3 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING COMPARED TO STANDARD BLOOD PRESSURE CONTROL ALONE FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA IN SPANISH, SWEDISH AND SWISS SETTINGS
Abstract
Authors
AJ Palmer S Roze Valentine Wj L Annemans S Gabriel R Chen